Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America

Clinical Infectious Diseases

Volumn 39, Issue 9, 2004, Pages 1307-1313

  Mertz, Gregory J ^a,h   Miedzinski, Lil ^f   Goade, Diane ^a   Pavia, Andrew T ^b   Hjelle, Brian ^a   Hansbarger, Christine O ^a   Levy, Howard ^a,g   Koster, Frederick T ^a   Baum, Kenneth ^c   Lindemulder, Adeline ^f   Wang, Wenquan ^d   Riser, Laura ^d   Fernandez, Humberto ^e   Whitley, Richard J ^d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Valeant Pharmaceuticals International   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EXTRACORPOREAL OXYGENATION; FEMALE; HANTAVIRUS; HANTAVIRUS CARDIOPULMONARY SYNDROME; HANTAVIRUS PULMONARY SYNDROME; HUMAN; IMMUNOASSAY; LIVER TOXICITY; MALE; NEPHROTOXICITY; NORTH AMERICA; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SHOCK; SIN NOMBRE VIRUS;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HANTAVIRUS PULMONARY SYNDROME; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NORTH AMERICA; PLACEBOS; RIBAVIRIN;

EID: 7644244053     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425007     Document Type: Article

References (10)

1. Mertz GJ. Bunyaviridae: bunyaviruses, phleboviruses, nairoviruses and hantaviruses. In: Richmann DD, Whitley RJ, Hayden FG, eds. Clinical virology. 2nd ed. Washington, DC: American Society for Microbiology Press, 2002:921-48.
2. Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of the hantavirus pulmonary syndrome. Crit Care Med 1996;24:252-8.
3. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy for hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27.
4. Johnson KM. Ribavirin treatment of arenavirus, hantavirus, pneumovirus and paramyxovirus disease; topical and systemic therapy. In: Mills J, Corey L eds. Antiviral chemotherapy: new directions for clinical application and research. Vol 3. Englewood Cliffs, NJ: PTR Prentice Hall, 1993:229-49.
5. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999;4:211-9.
6. Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis 2000;181:1569-73.
7. Lee ET. Statistical methods or survival data analysis. 2nd ed. New York: John Wiley and Sons, 1992.
8. Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000;182:43-8.
9. Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 2003;77:9894-905.
10. Mertz GJ, Hjelle BL, Williams TM, Koster FT. Host responses in the hantavirus cardiopulmonary syndrome. In: Saluzzo JF, Dodet B, eds. Factors in the emergence and control of rodent-borne viral diseases. Paris: Elsevier, 1999;133-7.